Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
Gene|October 6, 2005
Characterisation of a novel p53 down-regulated promoter in intron 3 of the human MDM2 oncogeneHuiling Liang, John LunecExpert Review of Anticancer Therapy|June 7, 2008
Molecular pathology and potential therapeutic targets in soft-tissue sarcomaRadha Todd, John LunecCancers|January 11, 2022
Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53<sup>WT</sup> Uterine LeiomyosarcomaVictoria Chamberlain, Yvette Drew, John LunecCancer Metastasis Reviews|June 19, 2012
Non-glucose metabolism in cancer cells--is it all in the fat?Swethajit Biswas, John Lunec, Kim BartlettCancer Letters|July 26, 2003
The MYCN oncoprotein as a drug development targetXiaohong Lu, Andrew Pearson, John LunecCell Cycle (Georgetown, Tex.)|May 15, 2007
Cell cycle regulation targets of MYCN identified by gene expression microarraysEmma Bell, John Lunec, Deborah A TweddleOncotarget|May 26, 2016
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancerMaryam Zanjirband, Richard J Edmondson, John LunecCancer Letters|July 26, 2003
Genes co-amplified with MYCN in neuroblastoma: silent passengers or co-determinants of phenotype?Debbie Scott, Joanna Elsden, Andrew Pearson, et al.Molecular Cancer Therapeutics|February 3, 2016
Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent MannerArman Esfandiari, Thomas A Hawthorne, Sirintra Nakjang, et al.European Journal of Cancer (Oxford, England : 1990)|March 26, 2009
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell linesJoyce E Nutt, Kieran O'Toole, David Gonzalez, et al.Pageof 8